CLINICAL TRIALS PROFILE FOR REPAGLINIDE
✉ Email this page to a colleague
All Clinical Trials for REPAGLINIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00072904 ↗ | Diabetes Therapy to Improve BMI and Lung Function in CF | Completed | Cystic Fibrosis Foundation | Phase 3 | 2001-06-01 | To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF). |
| NCT00072904 ↗ | Diabetes Therapy to Improve BMI and Lung Function in CF | Completed | Cystic Fibrosis Foundation Therapeutics | Phase 3 | 2001-06-01 | To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF). |
| NCT00072904 ↗ | Diabetes Therapy to Improve BMI and Lung Function in CF | Completed | Novo Nordisk A/S | Phase 3 | 2001-06-01 | To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF). |
| NCT00072904 ↗ | Diabetes Therapy to Improve BMI and Lung Function in CF | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 2001-06-01 | To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF). |
| NCT00118950 ↗ | Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet | Completed | Steno Diabetes Center | Phase 4 | 2001-03-01 | Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with T2DM. Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for REPAGLINIDE
Condition Name
Clinical Trial Locations for REPAGLINIDE
Trials by Country
Clinical Trial Progress for REPAGLINIDE
Clinical Trial Phase
Clinical Trial Sponsors for REPAGLINIDE
Sponsor Name
